<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00081224</url>
  </required_header>
  <id_info>
    <org_study_id>NCCTG-N0346</org_study_id>
    <secondary_id>NCI-2012-02582</secondary_id>
    <secondary_id>CDR0000360666</secondary_id>
    <nct_id>NCT00081224</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum</brief_title>
  <official_title>A Phase II Trial Of Celecoxib (Celebrex) And Capecitabine (Xeloda) Combined With Pelvic Irradiation As Neoadjuvant Treatment Of Stage II or III Adenocarcinoma Of The Rectum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for&#xD;
      their growth. Drugs used in chemotherapy, such as capecitabine, work in different ways to&#xD;
      stop tumor cells from dividing so they stop growing or die. Radiation therapy uses&#xD;
      high-energy x-rays to damage tumor cells. Celecoxib may also make tumor cells more sensitive&#xD;
      to chemotherapy and radiation therapy. Giving celecoxib with capecitabine and radiation&#xD;
      therapy before surgery may shrink the tumor so that it can be removed.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving neoadjuvant celecoxib together with&#xD;
      capecitabine and pelvic irradiation works in treating patients with stage II or stage III&#xD;
      adenocarcinoma (cancer) of the rectum.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the pathological complete response rate in patients with stage II or III&#xD;
           adenocarcinoma of the rectum treated with neoadjuvant celecoxib and capecitabine in&#xD;
           combination with pelvic irradiation.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the safety and tolerability of this regimen in these patients.&#xD;
&#xD;
        -  Determine the rectal function of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the time to recurrence or progression and survival time of patients treated&#xD;
           with this regimen.&#xD;
&#xD;
        -  Correlate cellular and molecular markers in pretreatment tumor samples with response in&#xD;
           patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
        -  Neoadjuvant chemoradiotherapy: Patients receive oral celecoxib twice daily on days 1-7&#xD;
           and oral capecitabine twice daily on days 1-5. Patients undergo pelvic radiotherapy once&#xD;
           daily on days 1-5. Courses repeat weekly for 5.5 weeks.&#xD;
&#xD;
        -  Surgery: Patients undergo surgery 4-6 weeks after completion of neoadjuvant&#xD;
           chemoradiotherapy.&#xD;
&#xD;
        -  Adjuvant chemotherapy: Patients with a curative resection receive oral capecitabine&#xD;
           twice daily on days 1-14. Treatment repeats every 21 days for up to 4 courses.&#xD;
&#xD;
      Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year and then every 6 months for 4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of successes</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival time</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to event analyses</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression/recurrence</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first progression</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel function as measured by the Patient Bowel Function (Uniscale) Questionnaire, the FACT Diarrhea Subscale and the Mayo Bowel Function Questionnaire</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>celecoxib + capecitabine + radiation + surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant chemoradiotherapy: Patients receive oral celecoxib twice daily on days 1-7 and oral capecitabine twice daily on days 1-5. Patients undergo pelvic radiotherapy once daily on days 1-5. Courses repeat weekly for 5.5 weeks.&#xD;
Surgery: Patients undergo surgery 4-6 weeks after completion of neoadjuvant chemoradiotherapy.&#xD;
Adjuvant chemotherapy: Patients with a curative resection receive oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for up to 4 courses.&#xD;
Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
Patients are followed every 3 months for 1 year and then every 6 months for 4 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <arm_group_label>celecoxib + capecitabine + radiation + surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
    <arm_group_label>celecoxib + capecitabine + radiation + surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>celecoxib + capecitabine + radiation + surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery</intervention_name>
    <arm_group_label>celecoxib + capecitabine + radiation + surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed rectal adenocarcinoma&#xD;
&#xD;
               -  Clinical stage T3, N0, M0 OR any T, N1-3, M0 disease&#xD;
&#xD;
          -  Treatment with neoadjuvant chemotherapy and pelvic radiotherapy is indicated&#xD;
&#xD;
               -  All disease must be encompassable within standard pelvic radiotherapy fields&#xD;
&#xD;
          -  Distal border of the tumor must be at or below* the peritoneal reflection, defined as&#xD;
             within 12 cm of the anal verge by endoscopy NOTE: *If a portion of the tumor is below&#xD;
             the peritoneal reflection at the time of surgery, patients are eligible regardless of&#xD;
             the distance of the tumor determined at endoscopy&#xD;
&#xD;
          -  Tumor must be determined to be clinically resectable&#xD;
&#xD;
               -  Tumor may not be clinically fixed&#xD;
&#xD;
               -  Negative margins by routine examination of an unanesthetized patient&#xD;
&#xD;
          -  Transmural penetration of tumor through the muscularis propria by CT scan, endorectal&#xD;
             ultrasound, or MRI&#xD;
&#xD;
          -  No distant metastatic disease&#xD;
&#xD;
               -  No evidence of tumor outside the pelvis, including any of the following:&#xD;
&#xD;
                    -  Metastatic inguinal lymphadenopathy&#xD;
&#xD;
                    -  Peritoneal seeding&#xD;
&#xD;
                    -  Liver metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ upper limit of normal (ULN)&#xD;
&#xD;
          -  AST ≤ 3 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 4 times ULN if AST &lt; ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
          -  No renal impairment&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No symptomatic coronary artery disease&#xD;
&#xD;
          -  No uncontrolled cardiac arrhythmias&#xD;
&#xD;
          -  No myocardial infarction&#xD;
&#xD;
          -  No history of transient ischemic attacks or stroke&#xD;
&#xD;
          -  No other clinically significant cardiac disease&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No bleeding peptic ulcer disease within the past 12 months&#xD;
&#xD;
          -  No lack of physical integrity of the upper gastrointestinal tract&#xD;
&#xD;
          -  No malabsorption syndrome&#xD;
&#xD;
          -  No active inflammatory bowel disease&#xD;
&#xD;
          -  Must be able to swallow study drugs&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No dihydropyrimidine dehydrogenase deficiency&#xD;
&#xD;
          -  No history of uncontrolled seizures&#xD;
&#xD;
          -  No CNS disorders&#xD;
&#xD;
          -  No clinically significant psychiatric illness that would preclude study compliance or&#xD;
             giving informed consent&#xD;
&#xD;
          -  No other malignancy within the past 5 years except basal cell or squamous cell skin&#xD;
             cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No known sensitivity to NSAIDs, sulfonamides, or aspirin&#xD;
&#xD;
          -  No other serious medical illness that would preclude study treatment&#xD;
&#xD;
          -  No other conditions that would preclude study participation&#xD;
&#xD;
          -  Must be able to tolerate major surgery that may include abdominal-perineal resection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 30 days after study&#xD;
             treatment&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior systemic anticancer chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior radiotherapy to the pelvis&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 3 weeks since prior major surgery and recovered&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 7 days since prior nonsteroidal anti-inflammatory drugs (NSAIDs), including&#xD;
             aspirin&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No other concurrent anticancer treatment&#xD;
&#xD;
          -  No concurrent NSAIDs&#xD;
&#xD;
          -  No concurrent primary prophylactic therapy for hand-foot syndrome&#xD;
&#xD;
          -  No concurrent loperamide prophylaxis for diarrhea&#xD;
&#xD;
          -  No concurrent sorivudine or brivudine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Sinicrope, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>April 7, 2004</study_first_submitted>
  <study_first_submitted_qc>April 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2004</study_first_posted>
  <last_update_submitted>December 14, 2016</last_update_submitted>
  <last_update_submitted_qc>December 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>stage II rectal cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

